Try our Advanced Search for more refined results
APOTEX, INC. v. CEPHALON, INC. et al
Case Number:
2:06-cv-02768
Court:
Nature of Suit:
Judge:
Firms
- Akin Gump
- Armstrong Teasdale
- Brown McGarry
- Clark Hill
- Cravath Swaine
- Davis Graham
- Duane Morris
- Eckert Seamans
- Foley & Lardner
- Hangley Aronchick
- Harkins Cunningham
- Husch Blackwell
- Katten Muchin
- Kenny Nachwalter
- Kirkland & Ellis
- Langer Grogan
- Lewis Brisbois
- Marcus & Shapira
- Mintz Levin
- Montgomery McCracken
- Odom & Des Roches
- Robinson & Cole
- Stevens & Lee
- Venable LLP
- Volpe Koenig
- White and Williams
- Willkie Farr
- WilmerHale
Companies
Sectors & Industries:
-
July 07, 2017
Apotex, Ranbaxy End Pay-For-Delay Suit Over Narcolepsy Med
A Pennsylvania federal judge on Friday ended Canadian pharmaceutical company Apotex's pay-for-delay suit accusing generic-drug maker Ranbaxy of violating antitrust laws by accepting a settlement with Cephalon that improperly delayed generic alternatives to the narcolepsy medication Provigil from entry into the market.
-
June 14, 2017
Ranbaxy Pay-For-Delay Trial Kicks Off In Pa. Court
A Pennsylvania federal jury on Wednesday heard opening arguments in a closely watched pay-for-delay suit accusing drugmaker Ranbaxy of violating antitrust laws by accepting a settlement with rival Cephalon that improperly delayed generic forms of the narcolepsy medication Provigil from the market.
-
May 22, 2017
Damage Calculations Trimmed In Provigil Pay-For-Delay Row
A Pennsylvania federal judge has agreed to trim damage calculations put forward by an expert for Apotex Inc. in a dispute over how it was impacted by generic Provigil pay-for-delay deals it is challenging in court, ruling that two of the three offered calculations that relied on questionable assumptions.
-
January 26, 2016
3rd Circ. Stays Provigil Pay-For-Delay Trial During Cert. Appeal
The Third Circuit agreed Monday to stay an upcoming trial in a class action accusing Mylan and Ranbaxy Laboratories of inking pay-for-delay deals with Cephalon to keep generic versions of narcolepsy drug Provigil off the market while the appeals court weighs the decision to certify the class.
-
January 22, 2016
Drug Buyers Must Play Nice At Trial, Provigil Judge Says
Days before drugmakers including Cephalon Inc. are set to face a jury over an alleged pay-for-delay scheme involving its sleep-disorder medicine Provigil, a Pennsylvania federal judge has ruled the group suing isn't allowed to use certain prejudicial terms, bring up past guilty pleas or discuss pharmaceutical industry policies.
-
January 04, 2016
Provigil Antitrust Trial Should Be Postponed, Drug Cos. Say
Mylan and Ranbaxy Laboratories doubled down Monday on their request that the Third Circuit pause an upcoming pay-for-delay trial over Cephalon Inc.'s narcolepsy drug Provigil while the appeals court hears their challenge to class certification, saying such a stay is necessary.
-
December 22, 2015
Drug Cos. Ask 3rd Circ. To Halt Trial For Class Cert. Fight
Mylan Inc. and Ranbaxy Laboratories Inc. have urged the Third Circuit to halt an upcoming pay-for-delay trial over Cephalon Inc.'s narcolepsy drug Provigil while the appeals court hears their challenge to class certification, arguing Monday that the district court doesn't have jurisdiction over the case while the original appeal is pending.
-
December 17, 2015
Mylan, Ranbaxy Can't Halt Pay-For-Delay Suits Pending Appeal
A Pennsylvania federal judge on Thursday refused to pause pay-for-delay litigation against Mylan Inc. and Ranbaxy Laboratories Inc. over Cephalon Inc.'s narcolepsy drug Provigil while the Third Circuit hears the drug companies' appeal of a class certification order.
-
November 20, 2015
Mylan, Ranbaxy Urge Stay Of Provigil Pay-For-Delay Suits
Mylan Inc. and Ranbaxy Laboratories Ltd. on Thursday urged a Pennsylvania federal judge to stay three cases accusing them and others of accepting $300 million from Cephalon Inc. to delay generic versions of its narcolepsy drug Provigil, pending their effort to overturn a class certification order in the Third Circuit.
-
August 19, 2014
Apotex's Claim Of Provigil Monopoly To Be Decided At Trial
A Pennsylvania federal judge on Tuesday refused to grant Apotex Inc. summary judgment that Cephalon Inc. had monopoly power over the market for modafinil, the active ingredient in the narcolepsy drug Provigil, saying that disputed issues exist that should be resolved at trial.